Spironolactone: diuretic or disease‐modifying drug in heart failure with preserved ejection fraction? Universiteit Hasselt Vrije Universiteit Brussel
This article refers to 'Diuretic and renal effects of spirono-lactone and heart failure hospitalizations: a TOPCAT Americas analysis' by A.P. Kalogeropoulos et al., published in this issue on pages 1600-1610. With monthly costs of approximately US$12 in the USA and €5 in Europe, spironolactone is by a landslide the most cost-effective drug in the management of heart failure (HF) with reduced ejection fraction (HFrEF). In the Randomized Aldactone ...